Cancer patients may have an increased risk of developing second primary malignancies after immune checkpoint inhibitor therapy.
A 40-gene expression profile test can improve risk stratification for patients with CSCC, according to researchers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback